About us

David Angulo, M.D.

Dr. Angulo became President and Chief Executive Officer of SCYNEXIS, as well as a member of the Board of Directors, in January 2023. Dr. Angulo joined SCYNEXIS in 2015 as Chief Medical Officer. An infectious disease specialist with more than 20 years of experience in successful drug development, he previously served as Vice President, Research and Development of Brickell Biotech, Inc.

Prior to joining Brickell, Dr. Angulo held various senior positions at Stiefel Laboratories, Inc., a GSK company, including head of the clinical and medical departments. Dr. Angulo was also responsible for several development programs in the anti-infectives area at Schering-Plough Research Institute and was an infectious disease physician in a pediatric hospital. He received his medical degree from the Universidad de Guadalajara, Mexico, and has post-graduate degrees in pediatrics and infectious diseases.

Scott Sukenick

Mr. Sukenick joined SCYNEXIS as General Counsel in November 2017 after over a decade of addressing a diversity of legal challenges faced by innovative life sciences companies at all stages of development.

Mr. Sukenick most recently worked at Cooley LLP, where he focused on life sciences litigation and strategic intellectual property management. Prior to that, he worked at Patterson Belknap Webb & Tyler LLP, where he primarily represented pharmaceutical and medical device companies in patent litigation. He started his career at Simpson Thacher & Bartlett LLP, where his practice focused on complex commercial litigation and intellectual property transactional matters. Mr. Sukenick is a registered patent attorney. He obtained a B.S. in Biology and a B.A. in Chemistry from Duke University and a J.D. from Harvard University.

Sanjay Subramanian, MBA

Sanjay Subramanian joined SCYNEXIS as Chief Financial Officer in September 2026. He is an accomplished biopharmaceutical finance executive with more than 20 years of experience in finance, capital markets, business development, and corporate strategy. Prior to joining SCYNEXIS, Mr. Subramanian served as Chief Financial Officer and Head of Business Development at Inozyme Pharma, where he led finance, investor relations, legal, and business development activities and played a key role in the company’s acquisition by BioMarin Pharmaceutical. Previously, he served as Chief Financial Officer and Head of Corporate Development at Ocugen, Inc. Earlier in his career, he held finance leadership positions at Aralez Pharmaceuticals, Bausch Health Companies, and General Motors. Mr. Subramanian earned an M.B.A. from the MIT Sloan School of Management, a Master of Science from the Massachusetts Institute of Technology, a Master of Science from The Ohio State University, and a Bachelor of Science from the Indian Institute of Technology (IIT) Madras.

Daniella Gigante

Daniella Gigante joined SCYNEXIS to lead the Human Resources and IT functions in October 2020. She has over 22 years of Human Resources experience in various industries including Consulting, Banking, Pharmaceutical and Bio-technology. Prior to SCYNEXIS, Ms. Gigante spent 8 years at Allergan where she was the Executive Director of Talent Acquisition. Previously she worked at Pfizer and Schering-Plough responsible for leading Talent Acquisition teams. Prior to that she led an HR Reporting and Analytics team at Washington Mutual Bank. Ms. Gigante holds a Master of Arts in Industrial and Organizational Psychology from Fairleigh Dickinson University and a Bachelor of Arts in Psychology from Hofstra University.

Rossana Ferrara-Pontoriero, Ph.D.

Rossana Ferrara-Pontoriero joined SCYNEXIS in September 2016 and has held various leadership roles in Commercial, Business Development, Strategic Planning, and Alliance Management. Dr. Ferrara-Pontoriero is a Commercial and Business Development executive with over 11 years’ experience in the Pharmaceutical and Biotechnology industries. Prior to SCYNEXIS, she worked in Marketing roles at Celgene and Allergan as well as Global Commercial Assessments at Forest Laboratories. Dr. Ferrara-Pontoriero received her PhD in Medicinal Chemistry from Università degli Studi di Milano, her Master’s in Pharmacy from the Università degli Studi di Salerno, and her MBA in Pharmaceutical Management from Rutgers Business School.

Guy Macdonald

Mr. Macdonald joined the board in November 2014 and became Chairman in June 2015. Mr. Macdonald served as the President and Chief Executive Officer and member of the board of directors of Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH) from January 2008 to August 2019. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President of Operations of Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company. From 1981 to 2003, he served in various positions at Merck & Co., Inc. (NYSE: MRK), most recently as the Vice President for Anti-Infective and Hospital Products. Mr. Macdonald received an Honors Degree in biochemistry from Dundee University in Dundee, Scotland.

Armando Anido

Mr. Anido joined our Board in January 2019. He served as Chairman and Chief Executive Officer (CEO) of Zynerba Pharmaceuticals from October 2014 until it was acquired in October 2023. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. Prior to Zynerba, Mr. Anido served as CEO of two publicly traded companies. Most recently, he was the CEO of NuPathe Inc., which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, he led the company through FDA approval of its lead product, Zecuity®, the first transdermal patch for migraine, to pre-launch before the company’s acquisition by Teva. He also served as President and CEO of Auxilium Pharmaceuticals, a specialty pharmaceutical company acquired by Endo Pharmaceuticals, Inc. in January 2015. Under Mr. Anido’s leadership at Auxilium, sales grew from $42 million in 2005 to more than $260 million in 2011. Prior to Auxilium, Mr. Anido served as Executive Vice President, Sales and Marketing, at MedImmune, where Synagis, an anti-viral for RSV, became a blockbuster product, and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At Lederle, he was Vice President, Anti-Infectives, responsible for the commercialization of the anti-bacterials, Suprax and Zosyn. He was previously a member of the Boards of Directors of Altamira Therapeutics Ltd. (formerly Auris Medical Holding AG), Life Science PA, Adolor Corporation until it was sold to Cubist Pharmaceuticals in December 2011, and Aviragen Therapeutics, Inc. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.

Ann F. Hanham, Ph.D.

Dr. Hanham has served as a member of the board of directors since December 2008. Prior to becoming a Founding Partner and Managing Director of BAR Capital Management in December 2013, she was a General Partner with Burrill & Company, a life sciences venture capital firm, from 2000 to 2013. From 1998 to 2000, Dr. Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune, Inc. (Nasdaq: ITMN). From 1995 to 1998, she served as the Senior Director for Oncology Product Development at Otsuka Pharmaceutical, Inc. and from 1991 to 1995 as the Medical Director for Celtrix Pharmaceuticals Inc. From 1988 to 1991, Dr. Hanham worked for Becton Dickinson and Company (Nasdaq: BDX) in both regulatory and clinical affairs for the monoclonal antibody program, and from 1984 to 1988 as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. Dr. Hanham was previously a member of the boards of directors of HTG Molecular Diagnostics Inc., Acusphere Inc., Biomimetic Therapeutics Inc., Biotie Therapies Corp., Immunicon Corp., Targacept Inc., TLC, and Endocyte, Inc. Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986.

David Hastings

Mr. Hastings joined our Board in September 2015. Mr. Hastings has served as Chief Financial Officer of Trevi Therapeutics, Inc. (Nasdaq: TRVI), a publicly-traded biopharmaceutical company, since January 2026. Prior to Trevi, Mr. Hastings served as the Chief Financial Officer at Arbutus Biopharma Corp. (Nasdaq: ABUS), a publicly-traded biopharmaceutical company, from June 2018 to March 2025. From February 2015 to June 2017, Mr. Hastings served as the Senior Vice President and Chief Financial Officer of Unilife Corporation, a publicly-traded medical technology company, and from July 2016 to June 2017, Mr. Hastings also served as Unilife’s Chief Accounting Officer and Treasurer. Prior to joining Unilife, Mr. Hastings served as Executive Vice President and Chief Financial Officer at Incyte Corporation (Nasdaq: INCY), a publicly-traded biopharmaceutical company, from October 2003 to October 2014. From February 2000 to September 2003, Mr. Hastings served as Vice President, Chief Financial Officer and Treasurer of ArQule, Inc. (Nasdaq: ARQL). Mr. Hastings previously served on the boards of directors of VBL Therapeutics (Nasdaq:VBLT) and Entasis Therapeutics Holdings Inc. Mr. Hastings received his B.A. in Economics at the University of Vermont.

Philippe Tinmouth

Mr. Tinmouth joined our Board in December 2019. Mr. Tinmouth has been a Partner at Flagship Pioneering since September 2025. Prior to Flagship, Mr. Tinmouth served as a Senior Advisor to Mammoth Biosciences, Inc., a biotechnology company, from March 2025 through December 2025 and previously served as Chief Business and Strategy Officer from December 2022 through February 2025. From November 2021 through December 2022, Mr. Tinmouth served as Chief Business and Strategy Officer of Pardes Biosciences (Nasdaq:PRDS), a publicly-traded biopharmaceutical company. From October 2002 through his retirement in March 2020,Mr. Tinmouth served in various positions at Vertex Pharmaceuticals (Nasdaq: VRTX), a publicly traded biopharmaceutical company, most recently serving as Vice President and Head of Business Development & Alliance Management since July 2013. From 1997 to 2002, Mr. Tinmouth held various positions at Bain & Company, most recently serving as a Senior Manager in the Boston office, where he advised both Fortune 50 pharmaceutical companies and smaller biotechnology companies on growth strategies. Mr. Tinmouth has served as a mentor and advisor to biotech start-ups through both the Harvard Innovation Lab (Harvard iLab) and the Canadian Technology Accelerator. Early in his career, Mr. Tinmouth was a design engineer at Bombardier Aerospace, where he was a member of the flight test team for the Canadair Regional Jet. Mr. Tinmouth holds a Master’s Degree in Business Administration from Harvard Business School and a Bachelor’s Degree with Honors in Mechanical Engineering from Queen’s University in Canada.

Steven K. Burke, M.D.

Dr. Burke brings more than 30 years of industry experience, with a particular focus on drug development for chronic kidney disease. He has worked at Akebia Therapeutics, Inc. since 2019, and has served as its Senior Vice President, Chief Research and Development Officer and Chief Medical Officer since 2021. During his time, he has had a leadership role in the development of Vafseo® (vadadustat) for anemia due to chronic kidney disease and has supported Auryxia® (ferric citrate). He also oversees development programs for glomerular diseases and other investigational programs. Prior to joining Akebia, Dr. Burke founded Abfero Pharmaceuticals, Inc. and served on its board through its acquisition by Pharmacosmos A/S. Earlier in his career, Dr. Burke served as Senior Vice President and Chief Medical Officer of Proteon Therapeutics, Inc. from 2006 to 2019 and in senior positions at several other biotechnology companies including Genzyme Inc. Dr. Burke received an A.B. from Harvard College and an M.D. from Cornell University Medical School. He completed a residency and fellowship at Brigham and Women’s Hospital and is board certified in internal medicine and gastroenterology and has maintained a Massachusetts medical license since 1989.